Sign in →

Test Code LAB396 2,3-Dinor 11 Beta-Prostaglandin F2 Alpha, Random, Urine

Additional Codes

SQ: 23BPGM

MAYO: 23BPR


Ordering Guidance


Although a random urine collection is acceptable, the preferred specimen for 2,3-dinor-11beta-prostaglandin F2 alpha analysis is a 24-hour urine collection; order 23BPT / 2,3-Dinor 11 Beta-Prostaglandin F2 Alpha, 24 Hour, Urine.

 

If ordering this test with NMHR / N-Methylhistamine, Random, Urine, both tests must be ordered under different order numbers. They cannot share an order number.



Specimen Required


Patient Preparation: Patients taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have decreased concentrations of prostaglandin F2 alpha. If possible, discontinue for 2 weeks or 72 hours, respectively, prior to collecting a specimen.

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Container/Tube: Plastic, 5-mL tube

Specimen Volume: 5 mL

Collection Instructions: Collect a random urine specimen.


Secondary ID

606356

Useful For

Screening for mast cell activation disorders including systemic mastocytosis using random urine specimens

Profile Information

Test ID Reporting Name Available Separately Always Performed
R23BP 2,3-dinor 11B-Prostaglandin F2a No Yes
CRETR Creatinine, Random, U No Yes

Method Name

R23BP: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

CRETR: Enzymatic Colorimetric Assay

Reporting Name

2,3-dinor 11B-Prostaglandin F2a,RU

Specimen Type

Urine

Specimen Minimum Volume

3 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 14 days
  Frozen  30 days
  Ambient  8 hours

Reject Due To

  All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Reference Values

<1802 pg/mg creatinine

Method Description

2,3-Dinor-11beta-prostaglandin F2 alpha (2,3 BPG) is quantified in urine by liquid chromatography tandem mass spectrometry (LC-MS/MS). Deuterium-labeled 2,3-dinor-11beta-prostaglandin F2 alpha (d9-2,3 BPG) and reagent are added to all controls and specimens, which are then liquid/liquid extracted. The extractant is evaporated and samples and controls  then reconstituted. Chromatographic separation is achieved with an analytical column. This eluent is transferred to an API 5000 MS/MS. The ratios of the integrated peak heights of 2,3 BPG and d9-2,3 BPG internal standard are used to calculate the concentration of the analyte. All 2,3 BPG concentrations are normalized to urine creatinine levels.(Unpublished Mayo method)

 

Creatinine:

All 2,3 BPG concentrations are normalized to urine creatinine levels measured using a Roche cobas enzymatic method. The enzymatic method is based on the determination of sarcosine from creatinine with the aid of creatininase, creatinase, and sarcosine oxidase. The liberated hydrogen peroxide is measured via a modified Trinder reaction using a colorimetric indicator. Optimization of the buffer system and the colorimetric indicator enables the creatinine concentration to be quantified both precisely and specifically.(Package insert: Creatinine plus ver 2. Roche Diagnostics; V15.0, 03/2019)

Day(s) Performed

Tuesday, Thursday

Report Available

3 to 8 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

84150

82570

LOINC Code Information

Test ID Test Order Name Order LOINC Value
23BPR 2,3-dinor 11B-Prostaglandin F2a,RU 97658-9

 

Result ID Test Result Name Result LOINC Value
CRETR Creatinine, Random, U 2161-8
603459 2,3-dinor 11B-Prostaglandin F2a 97658-9